Amgen's most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $175.00 short call and a strike $185.00 long call offers a potential 29.03% return on risk over the next 31 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $175.00 by expiration. The full premium credit of $2.25 would be kept by the premium seller. The risk of $7.75 would be incurred if the stock rose above the $185.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.
The RSI indicator is at 21.39 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Who Had the Better Quarter: Gilead Sciences or Amgen?
Fri, 17 May 2019 16:29:13 +0000
Here's which one of these large-cap biotechs put up the best numbers in the first quarter.
Bulls Make Money, Bears Make Money and Hogs Get Slaughtered, Jim Cramer Says
Fri, 17 May 2019 11:33:00 +0000
That's Rule No. 5 of his ‘5 Rules for Trimming Your Winning Positions.'
Here Are The Biotech Winners Ahead Of 2019's Biggest Cancer Meeting
Thu, 16 May 2019 20:14:57 +0000
Biotech companies Iovance Biotherapeutics, MacroGenics and Mirati Therapeutics were among the winners in a slew of data for cancer treatments released late Wednesday. Stocks rose Thursday.
Amgen To Present At The RBC Healthcare Conference And The UBS Global Healthcare Conference
Thu, 16 May 2019 20:00:00 +0000
THOUSAND OAKS, Calif., May 16, 2019 /PRNewswire/ — Amgen (AMGN) will present at the RBC Health Care Conference at 8:30 a.m. ET and at the UBS Global Healthcare Conference at 2 p.m. ET on Tuesday, May 21, 2019, in New York City. Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present at both conferences. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
Here's Why Mirati Therapeutics Is Surging Today
Thu, 16 May 2019 18:47:00 +0000
Lackluster results from Amgen's KRAS inhibitor program are clearing a path for Mirati's candidate.
Also on Market Tamer…
Follow Us on Facebook